erythropoietin (PBL Therapeutics)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Nameerythropoietin (PBL Therapeutics)
Drug Alias Nameultra erythropoietinanemia therapeutics (PBL)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPBL Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPBL Therapeutics
Active IndicationsN/A
Inactive IndicationsAnemia

Other Information

ATC CodeN/A
Related LinksN/A